GlaxoSmithKline on Wednesday said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion as the British drugs giant restructures.
This article was originally published on this website.
GlaxoSmithKline on Wednesday said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion as the British drugs giant restructures.
This article was originally published on this website.
© 2022 HousingServices.ca
